Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Vaginal Carcinoma: early-phase trial registry

2 of 5 indexed Vaginal Carcinoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 2 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Vaginal Carcinoma: 5 US clinical trials tracked, 2 recruiting.

Vaginal Carcinoma is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Ohio State University Comprehensive Cancer Center, running 2 of these trials.

Enrollment posture brief

Registry condition vaginal-carcinoma

OPEN 2 | RECR 40% | LATE 0 | EARLY 3 | RANK #3391 | SPON 2

Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Vaginal Carcinoma (this)40%
Open-enrollment share among volume-matched conditions near Vaginal Carcinoma

Vaginal Carcinoma lists 2 open slots (40% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Vaginal Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Vaginal Carcinoma is recruiting below its size-band peers.

    2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Vaginal Carcinoma research.

    Ohio State University Comprehensive Cancer Center accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Most Vaginal Carcinoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 85 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.

  4. Vaginal Carcinoma splits between interventional and observational designs.

    3 interventional and 2 observational studies make up this index (60% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 23

Phase Distribution

PhaseTrial count
Phase 2 3

Named interventions

Most-linked intervention names on Vaginal Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Bupropion 150 mg XL Drug
1 trials
Pelvic Examination Procedure
1 trials
HPV vaccine, Imiquimod, and metformin combination therapy Drug
1 trials
Prasterone Drug
1 trials
Survey Other
1 trials
Questionnaire Administration Other
1 trials
Survey Administration Other
1 trials
Quality-of-Life Assessment Other
1 trials

US sites by state

Facility locations filed on Vaginal Carcinoma trials. A trial with sites in several states counts in each.

Texas 2 trials
Ohio 2 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Vaginal Carcinoma page

5 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Vaginal Carcinoma condition card totals 5 registered trials; most-linked intervention Bupropion 150 mg XL; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.